$SESN News Article - Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium for Non-Muscle Invasive Bladder Cancer https://marketwirenews.com/news-releases/sese...21160.html